anastrozole has been researched along with Ovarian Neoplasms in 20 studies
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 5.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "A subset of patients with estrogen- or progesterone-positive platinum-resistant or platinum-refractory recurrent epithelial ovarian cancers derives clinical benefit from anastrozole, with acceptable toxicity." | 5.24 | Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. ( Beale, PJ; Bonaventura, A; DeFazio, A; Friedlander, ML; Goh, JCH; Grant, PT; Hadley, AM; Mapagu, C; Martyn, J; McNally, OM; Mileshkin, LR; OʼConnell, RL; Scurry, J; Sjoquist, KM, 2017) |
| "Anastrozole was well-tolerated." | 2.90 | PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; Davis, A; deFazio, A; Friedlander, M; Goh, J; Grant, P; Kennedy, CJ; McNally, O; Mileshkin, L; Moujaber, T; O'Connell, RL; Scurry, J; Sjoquist, KM; Sykes, P; Tan, K; Tang, M, 2019) |
| "Anastrozole was well tolerated." | 2.90 | PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; DeFazio, A; Friedlander, M; Goh, J; Grant, P; Kok, PS; Mapagu, C; O'Connell, RL; Scurry, J; Sjoquist, K, 2019) |
| "After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled." | 1.72 | [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report]. ( Fukino, S; Hamasaki, T; Kodama, W; Nishimura, K; Oota, R; Suo, K; Takagi, Y; Tanaka, Y, 2022) |
| "Letrozole was administered post operatively in 55." | 1.46 | Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? ( Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G, 2017) |
| "Blepharitis was noted in 68 of 82 eyes (73%), decreased or poor tear function in 24 eyes (29%), conjunctival injection in 18 eyes (22%) and superficial punctate keratitis in 12 eyes (29%)." | 1.39 | Dry eye syndrome in aromatase inhibitor users. ( Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K, 2013) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 1.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, Y | 3 |
| Oota, R | 3 |
| Takagi, Y | 3 |
| Kodama, W | 3 |
| Nishimura, K | 3 |
| Hamasaki, T | 3 |
| Fukino, S | 3 |
| Suo, K | 3 |
| Quesada, S | 3 |
| Bini, M | 3 |
| Lebreton, C | 3 |
| Ray-Coquard, I | 3 |
| Banerjee, SN | 1 |
| Tang, M | 2 |
| O'Connell, RL | 3 |
| Sjoquist, K | 2 |
| Clamp, AR | 1 |
| Millan, D | 1 |
| Nottley, S | 1 |
| Lord, R | 1 |
| Mullassery, VM | 1 |
| Hall, M | 1 |
| Gourley, C | 2 |
| Bonaventura, T | 3 |
| Goh, JC | 1 |
| Sykes, P | 2 |
| Grant, PT | 2 |
| McNally, O | 2 |
| Alexander, L | 1 |
| Kelly, C | 1 |
| Carty, K | 1 |
| Divers, L | 1 |
| Bradshaw, N | 1 |
| Edmondson, RJ | 1 |
| Friedlander, M | 3 |
| Bonaventura, A | 1 |
| OʼConnell, RL | 1 |
| Mapagu, C | 2 |
| Beale, PJ | 1 |
| McNally, OM | 1 |
| Mileshkin, LR | 1 |
| Hadley, AM | 1 |
| Goh, JCH | 1 |
| Sjoquist, KM | 2 |
| Martyn, J | 1 |
| DeFazio, A | 3 |
| Scurry, J | 3 |
| Friedlander, ML | 1 |
| Fader, AN | 1 |
| Bergstrom, J | 1 |
| Jernigan, A | 1 |
| Tanner, EJ | 1 |
| Roche, KL | 1 |
| Stone, RL | 1 |
| Levinson, KL | 1 |
| Ricci, S | 1 |
| Wethingon, S | 1 |
| Wang, TL | 1 |
| Shih, IM | 1 |
| Yang, B | 1 |
| Zhang, G | 1 |
| Armstrong, DK | 1 |
| Gaillard, S | 1 |
| Michener, C | 1 |
| DeBernardo, R | 1 |
| Rose, PG | 1 |
| Amant, F | 2 |
| Beale, P | 2 |
| Grant, P | 2 |
| Davis, A | 1 |
| Mileshkin, L | 1 |
| Moujaber, T | 1 |
| Kennedy, CJ | 1 |
| Tan, K | 1 |
| Antill, Y | 2 |
| Goh, J | 2 |
| Kok, PS | 1 |
| Deval, B | 1 |
| Rousset, P | 1 |
| Bigenwald, C | 1 |
| Nogales, FF | 1 |
| Alexandre, J | 1 |
| Esfahani, K | 1 |
| Ferrario, C | 1 |
| Le, P | 1 |
| Panasci, L | 1 |
| van Meurs, HS | 1 |
| van der Velden, J | 1 |
| Buist, MR | 1 |
| van Driel, WJ | 1 |
| Kenter, GG | 1 |
| van Lonkhuijzen, LR | 1 |
| Gershenson, DM | 1 |
| Bodurka, DC | 1 |
| Coleman, RL | 1 |
| Lu, KH | 1 |
| Malpica, A | 1 |
| Sun, CC | 1 |
| Korach, J | 1 |
| Perri, T | 1 |
| Beiner, M | 1 |
| Davidzon, T | 1 |
| Fridman, E | 1 |
| Ben-Baruch, G | 1 |
| Blinman, P | 1 |
| Tattersall, MH | 1 |
| Abdul Munem, A | 1 |
| Al-Bahrani, B | 1 |
| Mehdi, I | 1 |
| Kamona, A | 1 |
| Nadas, AM | 1 |
| Turaka, K | 1 |
| Nottage, JM | 1 |
| Hammersmith, KM | 1 |
| Nagra, PK | 1 |
| Rapuano, CJ | 1 |
| del Carmen, MG | 1 |
| Fuller, AF | 1 |
| Matulonis, U | 1 |
| Horick, NK | 1 |
| Goodman, A | 1 |
| Duska, LR | 1 |
| Penson, R | 1 |
| Campos, S | 1 |
| Roche, M | 1 |
| Seiden, MV | 1 |
| Rao, GG | 1 |
| Miller, DS | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Tanaka, T | 1 |
| Murata, T | 1 |
| Kamimura, K | 1 |
| Deguchi, Y | 1 |
| Nonogaki, H | 1 |
| Yasumizu, R | 1 |
| Freeman, SA | 1 |
| Modesitt, SC | 1 |
3 reviews available for anastrozole and Ovarian Neoplasms
| Article | Year |
|---|---|
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Topics: Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recur | 2012 |
Clinical applications of hormonal therapy in ovarian cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Dose-Response Rela | 2005 |
5 trials available for anastrozole and Ovarian Neoplasms
| Article | Year |
|---|---|
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Topics: Adult; Aged; Anastrozole; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recurrence, Lo | 2021 |
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epi | 2017 |
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Cystadenoc | 2019 |
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; CA- | 2019 |
Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Fallopian Tube Neoplasms; Fem | 2003 |
12 other studies available for anastrozole and Ovarian Neoplasms
| Article | Year |
|---|---|
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2017 |
Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive.
Topics: Anastrozole; Aromatase; Estrogens; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pa | 2019 |
Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor.
Topics: Anastrozole; Aromatase Inhibitors; Ependymoma; Female; Humans; Middle Aged; Nitriles; Ovarian Neopla | 2014 |
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Female; Humans; | 2014 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuv | 2015 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2017 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Mid | 2009 |
A case of uterine tumour resembling ovarian sex cord tumour responding to second-line, single agent anastrazole.
Topics: Anastrozole; Diagnosis, Differential; Female; Humans; Middle Aged; Nitriles; Ovarian Neoplasms; Tria | 2009 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Hu | 2006 |